Firebrick Pharma Ltd has released a press release.
Firebrick Investor Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- Firebrick Receives $1.81m R&D Tax Incentive
- September 2023 Quarterly Activity Report & Appendix 4C
- Update on Nasodine Trial and Forward Plans
- Phase 3 Common Cold Trial Results
- Appendix 4E & Annual Report FY23
Later from Firebrick Pharma
- December 2023 Quarterly Activity Report & Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2023
- Nasodine Nasal Spray Launch in the USA
- March 2024 Quarterly Activity Report & Appendix 4C
- Firebrick Raises $800,000 via Placement
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma